Related Experiment Videos
Novel therapeutic strategies to selectively kill cancer cells
1Human Gene Therapy Research Institute, Des Moines, IA 50309, USA. rekha.panchal@worldnet.att.net
Abstract:
Tumor invasion, metastasis, and resistance to chemotherapeutic drugs or radiation are major obstacles for the successful treatment of cancer. To overcome some of these limitations, therapeutic strategies that increase the specificity and efficacy and reduce the toxicity of the anti-cancer drugs or toxins are being explored. Cancer cells overexpress specific protein antigens and carbohydrate structures that may function as cell surface receptors. These cancer cell specific markers can be exploited while designing new cancer therapies. Monoclonal antibodies that have been humanized to reduce immunogenicity and targeted to specific antigens on cancer cells, enzyme-monoclonal antibody/prodrug conjugates that will selectively kill the target cells following drug activation, and recombinant toxins are some of the novel classes of agents in development. Another novel approach being investigated to treat cancers is the use of inactive pore-forming toxins with built-in biological "triggers" that will activate the toxin following a biological stimulus. These pore-forming cytolytic toxins can be rendered active by tumor-specific proteases, that are often overexpressed in cancer cells, thereby targeting the toxic effects. Such pore-forming or membrane-acting toxins may serve as novel cytolytic agents against solid tumors, which, to date, have proved to be more resistant to conventional toxins.
Insights
Novel cancer therapies are being developed to overcome tumor invasion, metastasis, and drug resistance. Researchers are exploring targeted toxins, like pore-forming toxins activated by tumor-specific proteases, to enhance treatment efficacy and reduce toxicity.
Area of Science:
- Oncology
- Biotechnology
- Drug Development
Background:
- Cancer treatment faces challenges including tumor invasion, metastasis, and resistance to conventional therapies.
- Cancer cells exhibit unique surface markers, such as specific protein antigens and carbohydrate structures, offering potential targets for therapeutic intervention.
- Current anti-cancer strategies aim to improve specificity and efficacy while minimizing drug toxicity.
Purpose of the Study:
- To explore novel therapeutic strategies for cancer treatment that overcome limitations of existing methods.
- To investigate the potential of exploiting cancer cell-specific markers for targeted drug delivery and action.
- To evaluate the use of engineered toxins as a new class of anti-cancer agents.
Main Methods:
- Development of humanized monoclonal antibodies targeting cancer cell-specific antigens.
- Design of enzyme-monoclonal antibody/prodrug conjugates for selective cancer cell killing.
- Investigation of inactive pore-forming toxins with biological triggers, activated by tumor-specific proteases.
Main Results:
- Humanized monoclonal antibodies offer reduced immunogenicity for targeted cancer therapy.
- Enzyme-monoclonal antibody/prodrug conjugates demonstrate selective tumor cell killing upon drug activation.
- Pore-forming toxins, activated by tumor-specific proteases, show promise as cytolytic agents against solid tumors.
Conclusions:
- Targeted therapies, including engineered antibodies and toxins, represent a promising avenue for improving cancer treatment outcomes.
- Exploiting cancer-specific markers and utilizing tumor-activated toxins can enhance therapeutic efficacy and reduce systemic toxicity.
- Pore-forming toxins offer a novel approach to combatting solid tumors, which are often resistant to conventional treatments.